中国基层医药
中國基層醫藥
중국기층의약
Chinese Journal of Primary Medicine and Pharmacy
2015年
18期
2802-2805
,共4页
胸腔积液,恶性%癌,非小细胞肺%鸦胆子油乳
胸腔積液,噁性%癌,非小細胞肺%鴉膽子油乳
흉강적액,악성%암,비소세포폐%아담자유유
Pleural effusion,Malignant%Carcinoma,Non -Small -Cell Lung%Brucea javanica oil emulsion
目的：观察鸦胆子油乳联合 TP 方案双径路治疗非小细胞肺癌（NSCLC）恶性胸腔积液的近期疗效和不良反应。方法收集经病理学确诊的 NSCLC 恶性胸腔积液患者91例，均以胸腔内置入中心静脉导管引流胸腔积液，按治疗方式分为 A 组（21例）：胸腔内注入鸦胆子油乳每次60 mL，2次／周；B 组（33例）：紫杉醇150 mg／m2第1天静脉化疗，顺铂60 mg／m2＋0．9％氯化钠注射液30 mL 第1天胸腔内注入，3周重复；C组（38例）：联合应用 A 组和 B 组治疗；治疗6周后比较三组近期疗效及不良反应。结果与 A、B 组比较，C组客观缓解率（81．6％）最高（χ2＝8．605，P ＜0．05），完全缓解率（55．3％）最高（χ2＝10．384，P ＜0．05），进展率（5.3％）最低（χ2＝8．649，P ＜0．05）；三组均未出现严重不良反应，A 组未发生白细胞减少，比较 B、C 组，差异有统计学意义（χ2＝8．999，P ＜0．05）。结论鸦胆子油乳联合 TP 方案双径路治疗 NSCLC 恶性胸腔积液疗效较高，优于单独化疗或腔内治疗，不良反应可耐受。
目的：觀察鴉膽子油乳聯閤 TP 方案雙徑路治療非小細胞肺癌（NSCLC）噁性胸腔積液的近期療效和不良反應。方法收集經病理學確診的 NSCLC 噁性胸腔積液患者91例，均以胸腔內置入中心靜脈導管引流胸腔積液，按治療方式分為 A 組（21例）：胸腔內註入鴉膽子油乳每次60 mL，2次／週；B 組（33例）：紫杉醇150 mg／m2第1天靜脈化療，順鉑60 mg／m2＋0．9％氯化鈉註射液30 mL 第1天胸腔內註入，3週重複；C組（38例）：聯閤應用 A 組和 B 組治療；治療6週後比較三組近期療效及不良反應。結果與 A、B 組比較，C組客觀緩解率（81．6％）最高（χ2＝8．605，P ＜0．05），完全緩解率（55．3％）最高（χ2＝10．384，P ＜0．05），進展率（5.3％）最低（χ2＝8．649，P ＜0．05）；三組均未齣現嚴重不良反應，A 組未髮生白細胞減少，比較 B、C 組，差異有統計學意義（χ2＝8．999，P ＜0．05）。結論鴉膽子油乳聯閤 TP 方案雙徑路治療 NSCLC 噁性胸腔積液療效較高，優于單獨化療或腔內治療，不良反應可耐受。
목적：관찰아담자유유연합 TP 방안쌍경로치료비소세포폐암（NSCLC）악성흉강적액적근기료효화불량반응。방법수집경병이학학진적 NSCLC 악성흉강적액환자91례，균이흉강내치입중심정맥도관인류흉강적액，안치료방식분위 A 조（21례）：흉강내주입아담자유유매차60 mL，2차／주；B 조（33례）：자삼순150 mg／m2제1천정맥화료，순박60 mg／m2＋0．9％록화납주사액30 mL 제1천흉강내주입，3주중복；C조（38례）：연합응용 A 조화 B 조치료；치료6주후비교삼조근기료효급불량반응。결과여 A、B 조비교，C조객관완해솔（81．6％）최고（χ2＝8．605，P ＜0．05），완전완해솔（55．3％）최고（χ2＝10．384，P ＜0．05），진전솔（5.3％）최저（χ2＝8．649，P ＜0．05）；삼조균미출현엄중불량반응，A 조미발생백세포감소，비교 B、C 조，차이유통계학의의（χ2＝8．999，P ＜0．05）。결론아담자유유연합 TP 방안쌍경로치료 NSCLC 악성흉강적액료효교고，우우단독화료혹강내치료，불량반응가내수。
Objective To evaluate short -term clinical efficacy and adverse effects of brucea javanica oil emulsion(BJOE)combined with TP regimen in treating malignant pleural effusion(MPE)of non -small cell lung cancer(NSCLC)by double -way chemotherapy.Methods Totally 91 patients with MPE of NSCLC diagnosed by pathology were builted into the central venous catheter.The patients were assigned to group A,B and C according to therapies.Group A(21 cases)accepted infusion of BJOE 60mL into thoracic cavity twice a week.Group B(33 cases) accepted TP regime therapy,which included paclitaxel(TAX)intravenous chemotherapy at a dose of 150mg/m2 and cisplatin(DDP)injecting into thoracic cavity at a dose of 60mg +0.9% sodium chloride injection 30mL in first day, the therapy was repeated every 3 weeks.Group C(38 cases)combined the therapies of group A′s and B′s.Clinical efficacy and adverse effects were evaluated after 6 weeks.Results The objective response rate(81.6%)for group C was higher than group A or B(χ2 =8.605,P <0.05),the same result were in CR ratio(55.3%)(χ2 =10.384,P <0.05)and PD ratio(5.3%)(χ2 =8.649,P <0.05).There were no serious adverse effects in the three groups.The occurring rate of white blood cell reduction in group A was lower than those of group B and C,there was statistically significance(χ2 =8.999,P <0.05).Conclusion The efficacy of BJOE combined with TP regimen in treating MPE of NSCLC by double -way chemotherapy is better than that of single chemotherapy or alone intrathoracic treatment, and the adverse effects could be well tolerated.
